Home About us Contact
|
Home About us Contact | ||
|
|
||
Prophylactic Effect (prophylactic + effect)
Selected AbstractsProphylactic effect of recombinant factor VIIa with congenital factor VII deficiencyHAEMOPHILIA, Issue 4 2008M. KARIMI No abstract is available for this article. [source] Prophylactic effect of clarithromycin in skin flap complications in cochlear implants surgery,THE LARYNGOSCOPE, Issue 10 2009Juan Garcia-Valdecasas MD Abstract Objectives/Hypothesis: To assess the usefulness of postoperative clarithromycin versus classical postoperative prophylaxis with occlusive dressing to prevent cochlear implant skin flap complications. Study Design: Cohort study. Methods: Surgical site infections were compared in four groups: 1) ceramic/classical postoperative cares (21 patients), 2) titanium-silicon/classical postoperative cares (75), 3) ceramic/clarithromycin (24), and 4) titanium-silicon/clarithromycin (76). Preoperative ceftriaxone was systematically used in all patients in all four groups. Patients were followed up for at least 4 months. Attributable risk and number needed to treat were calculated. Results: All infections appeared in titanium-silicon covered implants, and the risk of surgical site infection was 8.1 times higher in patients treated only with ceftriaxone and classical postoperative prophylaxis compared to those also given clarithromycin. Eleven patients needed to receive clarithromycin to avoid surgical infection. Conclusions: Long-term treatment with low-dose clarithromycin may reduce the incidence of surgical site infections. Laryngoscope, 2009 [source] Lithium treatment in Aarhus: contributions and controversies through half a centuryACTA PSYCHIATRICA SCANDINAVICA, Issue 2004Per Vestergaard In 1954 the first of several hundred publications on the use of lithium for treatment of affective disorders, lithium's unwanted effects, and its pharmacology was authored at the Aarhus University Psychiatric Hospital, the majority with Professor, now emeritus, Mogens Schou playing the principal part. The early part of this long series of papers highlights the pharmacology of lithium with its renal excretion, low therapeutic index, and ensuing risk of intoxication, the prophylactic effect not only against manic episodes but also the depressive ones and finally the long-term renal structural and functional impairment. Later papers present the problems related to lithium's lower effectiveness in routine clinical use, the problems of non-adherence, the dose effect relationships, and the problems inherent to establishing effective treatment service delivery. The present priority of the Aarhus lithium group is the simple large scale pragmatic effectiveness studies in which, together with domestic and foreign collaborators, we compare the long-term effectiveness of lithium with new promising drugs with mood stabilizing properties. The story of treatment with lithium in aarhus highlights important steps in the development of effective and comprehensive treatments for bipolar patients. [source] Combination of low-dose mirtazapine and ibuprofen for prophylaxis of chronic tension-type headacheEUROPEAN JOURNAL OF NEUROLOGY, Issue 2 2007L. Bendtsen Chronic headaches are difficult to treat and represent the biggest challenge in headache centres. Mirtazapine has a prophylactic and ibuprofen an acute effect in tension-type headache. Combination therapy may increase efficacy and lower side effects. We aimed to evaluate the prophylactic effect of a combination of low-dose mirtazapine and ibuprofen in chronic tension-type headache. Ninety-three patients were included in the double-blind, placebo-controlled, parallel trial. Following a 4-week run-in period they were randomized to four groups for treatment with a combination of mirtazapine 4.5 mg and ibuprofen 400 mg, placebo, mirtazapine 4.5 mg or ibuprofen 400 mg daily for 8 weeks. Eighty-four patients completed the study. The primary efficacy parameter, change in area under the headache curve from run-in to the last 4 weeks of treatment, did not differ between combination therapy (190) and placebo (219), P = 0.85. Explanatory analyses revealed worsening of headache already in the third week of treatment with ibuprofen alone. In conclusion, the combination of low-dose mirtazapine and ibuprofen is not effective for the treatment of chronic tension-type headache. Moreover, the study suggests that daily intake of ibuprofen worsens headache already after few weeks in chronic tension-type headache. [source] Clonazepam as a therapeutic adjunct to improve the management of depression: a brief reviewHUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 3 2009*Article first published online: 27 MAR 200, Shigeru Morishita Abstract Clonazepam, first used for seizure disorders, is now increasingly used to treat affective disorders. We summarize the use of clonazepam to improve the management of depression. Clonazepam is useful for treatment-resistant and/or protracted depression, as well as for acceleration of response to conventional antidepressants. Clonazepam is at this time recommended for use in combination with SSRIs (fluoxetine, fluvoxamine, sertraline) as an antidepressant, and should be used at a dosage of 2.5,6.0,mg/day. If clonazepam is effective, a response should be observed within 2,4 weeks. It is significantly more effective for unipolar than for bipolar depression. Low-dose, long-term treatment with clonazepam exhibits a prophylactic effect against recurrence of depression. Although the mechanism of action of clonazepam has not yet been established, some investigators have been suggested that it involves enhancement of anti-anxiety effects, anticonvulsant effects on subclinical epilepsy, increase in 5-HT/monoamine synthesis or decrease in 5-HT receptor sensitivity mediated through the GABA system, and regulate in GABA activity. Copyright © 2009 John Wiley & Sons, Ltd. [source] Untersuchungen zur prophylaktischen Wirkung der Verfütterung eines Probiotikums und von erregerspezifischen Kolostrum- und Dotterantikörpern bei neugeborenen KälbernJOURNAL OF ANIMAL PHYSIOLOGY AND NUTRITION, Issue 3-4 2000M. H. Von Erhard Studies on the prophylactic effect of feeding probiotics, pathogen-specific colostrum antibodies or egg yolk antibodies in newborn calves The prophylactic efficacy of feeding probiotics, specific egg yolk antibodies and specific colostrum antibodies on neonatal diarrhoea was investigated in a field trial with calves, grouped (n = 39/40 per group) according to the following treatments: Group I: feeding no additive; Group II: feeding probiotics (5 g powder/day with Bacillus cereus var. toyoi); Group III: feeding egg powder (10 g/day with specific egg yolk antibodies against rotavirus, coronavirus and Escherichia coli F5); Group IV: feeding colostrum antibodies (10 ml/day containing 1 g bovine immunoglobulins with specific antibodies against rotavirus, coronavirus and E. coli antigens); Group V: feeding egg powder together with probiotics (according to group II and III). The additives were given twice daily with the meal from day 2 to day 14 post-natum. The presence of infectious agents was proved in fecal samples of all calves. Intestinal infections with rotavirus (30.8% of the calves) predominated compared to those with coronavirus (7.1%), E. coli F5 (1.5%) and cryptosporidia (24.2%). In contrast to earlier studies, the manifestation of diarrhoea did not differ significantly between the five groups. Only the growth rate of the calves between day 2 and day 14 of life as a measure of their welfare showed treatmentFspecific differences. The control group (I) showed the lowest body weight gain of about 5.8 kg (SD 5.0), whereas in the treated groups it averaged 6.3 kg (SD 4.1, p = 0,60; group II), 6.8 kg (SD 4.3, p = 0.36; group III), 6.9 kg (SD 4.7, p = 0.61; group IV) and 7.7 kg (SD 4.9, p = 0.08; group V). Considering only the rotavirus-positive calves the body weight gain of the control group (I) was 3.5 kg (SD 4.8) and of the treated groups was 3.8 kg (SD 3.3, p = 0.65; II), 5.0 kg (SD 3.5, p = 0.54; III), 6.6 kg (SD 4.5, p = 0.05; IV) and 6.1 kg (SD 5.0, p = 0.13; V). Obviously, the feeding of antibodies from colostrum or from egg powder does increase the mean body weight gain. The feeding of probiotics alone has nearly no effect. However, in the combination with specific egg antibodies probiotics seem to have a synergistic effect. In serum from the 198 newborn calves the IgG concentration averaged 4.9 mg/ml serum (SD 3.3). From 93 dams of these calves a sample of the first colostrum could be obtained showing a mean IgG concentration of 22.0 mg/ml (SD 11.0). IgG levels in the colostrum and in the serum have been positively correlated (r = 0.37, p < 0.05). Calves with a high intensity of diarrhoea had a significantly (p = 0.01) lower mean IgG serum level (3.7 mg/ml; n = 36; SD 2.5) than calves without diarrhoea (5.6 mg/ml; n = 75; SD 4.0). In Rahmen eines Feldversuches wurde die prophylaktische Wirksamkeit verschiedener Futteradditiva (Probiotikum, spezifische Dotterantikörper, spezifische Kolostrumantikörper) bei der neonatalen Kälberdiarrhoe untersucht. Dazu wurden die Kälber entsprechend der Behandlung in folgende fünf Gruppen (je n = 39/40) eingeteilt: I: Keine Futterzusatzstoffe, II: Verfütterung eines Probiotikums (5 g Pulver/Tag mit Bacillus cereus var. toyoi), III: Verfütterung von Eipulver (10 g/Tag mit spezifischen Dotterantikörpern gegen Rotaviren, Coronaviren und E. coli F5), IV: Verfütterung von Kolostrumantikörpern (10 ml/Tag mit 1 g bovinen Immunglobulin mit spezifischen Antikörpern gegen Rotaviren, Coronaviren und Escherichia coli Antigene), V: Verfütterung von Eipulver zusammen mit einem Probiotikum (analog den Gruppen II und III). Die Prophylaktika wurden zwei Mal täglich vom 2. bis zum 14. Lebenstag mit der Tränke verabreicht. Bei allen Kälbern wurde ein Erregernachweis im Kot geführt. Rotaviren (30,8%) konnten im Vergleich zu Coronaviren (7,1%), E. coli F5 (1,5%) und Kryptosporidien (24,2%) häufiger nachgewiesen werden. Im Gegensatz zu früheren Studien konnten hinsichtlich des Durchfallgeschehens keine signifikanten Unterschiede zwischen den Gruppen festgestellt werden. Nur die Körperge wichtszunahme der Kälber zwischen 2. und 14. Lebenstag zeigte behandlungsspezifische Unterschiede. Die Kontrollgruppe (I) verbuchte mit 5,8 kg (SD 5,0) die niedrigste Körpergewichtszunahme. Verglichen damit lag die Zunahme der behandelten Gruppen bei 6,3 (SD 4,1; p = 0,60; Gruppe II), 6,8 kg (SD 4,3; p = 0,36; Gruppe III), 6,9 kg (SD 4,7, p = 0,61; Gruppe IV) und bei 7,7 kg (SD 4,9, p = 0,08; Gruppe V). Bei Rotavirus-positiven Kälbern war eine Körpergewichtszunahme von 3,5 kg (SD 4,8; Kontrollgruppe), 3,8 kg (SD 3,3, p = 0,65; Gruppe II), 5,0 kg (SD 3,5, p = 0,54; Gruppe III), 6,6 kg (SD 4,5, p = 0,05; Gruppe IV) und von 6,1 kg (SD 5.0, p = 0,13; Gruppe V) zu verzeichnen. Offensichtlich verhindert die prophylaktische Verfütterung von Kolostrum- oder Dotterantikörpern eine infektionsbedingte Verminderung der Körpergewichtszunahme. Die Applikation des Probiotikums alleine zeigte keinen vergleichbaren Effekt. Allerdings ist eine synergistische Wirkung in Kombination mit Antikörpern nicht auszuschließen. In den Seren der 198 neugeborenen Kälber wurde eine mittlere Immunglobulin G (IgG)-Konzentration von 4,9 mg/ml (SD 3,3) gemessen. Von 93 Muttertieren dieser Kälber konnte das Erstgemelk genommen werden, das eine mittlere IgG-Konzentration von 22,0 mg/ml (SD 11,0) aufwies. Die IgG-Gehalte in den Kolostrumproben und den Kälberseren zeigten eine Korrelation von r = 0,37 (p < 0,05). Kälber mit hochgradigem Durchfall hatten mit 3,7 mg/ml Serum (n = 36, SD 2,5) einen signifikant niedrigeren mittleren IgG-Wert als Kälber ohne Durchfall (5,6 mg/ml, n = 75, SD 4,0). [source] Metabolism of isometamidium in hepatocytes isolated from control and inducer-treated ratsJOURNAL OF VETERINARY PHARMACOLOGY & THERAPEUTICS, Issue 6 2006I. BOIBESSOT Little is known about the metabolism and mechanism of action of the trypanocide, isometamidium (ISM), the major drug used for prophylaxis of trypanosomiasis. We have investigated its metabolism and distribution in isolated rat hepatocytes using liquid chromatography-mass spectrometry and confocal laser scanning microscopy (CLSM). Two putative metabolites were formed, which were proposed to be a mono-acetyl derivative and an oxidized metabolite (SII). This is the first demonstration of the hepatic metabolism of ISM, as previous in vivo studies were hampered by dose-limiting toxicity and insensitive analytical methods. The intrinsic fluorescence of the drug enabled its intracellular uptake to be followed by CLSM. It is taken up rapidly into the nucleolus, nuclear membrane and endoplasmic reticulum within 5 min, and retained in the nucleus for at least 24 h. Persistent binding of ISM to cellular macromolecules may contribute to its prophylactic effect in vivo. Pretreatment of rats with 3-methylcholanthrene, phenobarbitone (PB) or the widely used pyrethroid pesticide, deltamethrin, resulted in an increase in metabolism of ISM to the proposed SII after 1 h incubation with hepatocytes. 3-methylcholanthrene was the most potent inducer, causing a maximal 19.5-fold induction of SII formation after exposure of hepatocytes to ISM for 1 h compared with formation by control hepatocytes. In comparison, at the 1 h timepoint deltamethrin pre-treatment caused a 10.2-fold induction, and PB only 8.2 fold. [source] Soy, isoflavones, and prostate cancerMOLECULAR NUTRITION & FOOD RESEARCH (FORMERLY NAHRUNG/FOOD), Issue 2 2009Le Jian Abstract Prostate cancer has marked geographic variations between countries. Genetic, epigenetic, and environmental factors co-contribute to the development of the cancer. The association between dietary factors and prostate cancer has been investigated and one explanation for the low incidence of the cancer in Asia might be high consumption of fresh vegetables including soybean and its products. Soybean is a species of legume contain high amount of isoflavones including genistein, daidzein, glycitein, and equol, which have a prophylactic effect on prostate cancer. In this article, epidemiological and laboratory studies on the relationship between soybeans, isoflavones and prostate cancer are reviewed and large scale multiethnic epidemiological studies are recommended. [source] Failure of inactivated influenza A vaccine to protect healthy children aged 6,24 monthsPEDIATRICS INTERNATIONAL, Issue 2 2004Taro Maeda AbstractBackground:,The efficacy of inactivated influenza vaccine in healthy infants and children younger than 24 months has not been confirmed. The aim of the present study was to determine the prophylactic effect of inactivated influenza vaccine against influenza A in healthy children aged 6,24 months. Methods:,Healthy infants and young children (6,24 months old) were immunized by subcutaneous injection of inactivated influenza vaccine before influenza seasons. Age matched children were randomly assigned as the control. These children were followed up from January to April in each year (2000, 2001 and 2002). The attack rates of influenza A infection was compared and statistically assessed. Results:,The attack rate of influenza A virus infection in the vaccine group and the control group were 14.8% (n = 27) vs 12.5% (n = 32) in 2000 (P = 0.526); 2.8% (n = 72) vs 7.2% (n = 69) in 2001 (P = 0.203); and 3.4% (n = 52) vs 8.9% (n = 56) in 2002 (P = 0.205). The attack rates of influenza A between the two groups were not significantly different. Conclusion:,Inactivated influenza vaccine did not reduce the attack rate of influenza A infection in 6,24 month old children. [source] Use of Dexamethasone on the Prophylaxis of Nausea and Vomiting After Tympanomastoid Surgery,THE LARYNGOSCOPE, Issue 7 2001Yun-Hou Liu MD Abstract Objective The aim of this study was to evaluate the prophylactic effect of dexamethasone on postoperative nausea and vomiting (PONV) in patients undergoing tympanomastoid surgery. Study Design Eighty patients (n = 40 in each of two groups) undergoing tympanomastoid surgery under general anesthesia were enrolled in this randomized, double-blind, placebo-controlled study. Methods After tracheal intubation, group 1 received 10 mg dexamethasone intravenously, whereas group 2 received saline intravenously. Several parameters concerning with the occurrence of PONV were evaluated. Results We found that dexamethasone reduced the total incidence of nausea and vomiting by 45%, with a 95% confidence interval of 26% to 64% (P <.001). Furthermore, dexamethasone reduced the incidence of vomiting episodes >4 times and the incidence of patients requiring rescue antiemetics (P <.05). Conclusion Dexamethasone at a dosage of 10 mg administered intravenously is effective in preventing PONV in patients undergoing tympanomastoid surgery. [source] The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970s and 1980sBIPOLAR DISORDERS, Issue 2 2001Janusz K Rybakowski Objectives: The aim of the study was to assess the prophylactic effect of long-term lithium administration in patients with bipolar mood disorders entering treatment in the 1970s and 1980s at the outpatient clinic of the Department of Psychiatry, University of Medical Sciences, Poznan, Poland. Methods: The clinical characteristics of two groups of patients before and during lithium therapy were compared, namely, the 60 bipolar patients who entered lithium prophylaxis in the 1970s and 49 patients who entered in the 1980s. Both groups received the drug over a 10-year period. Results: The patients who entered lithium in the 1970s had fewer previous episodes of depression and more of mania than the patients who entered the therapy in the 1980s, although the total number of affective episodes was similar in both groups. The overall prophylactic efficacy of lithium over a 10-year period of administration was similar in both groups, except for a trend towards a greater number of depressive episodes in the first year of lithium prophylaxis in the 1980s group. The excellent lithium responders constituted 35% of the 1970s patients and 27% of those in the 1980s group. The 1970s patients were maintained on a higher level of serum lithium compared to the patients in the 1980s group and had more lithium-induced side effects. Conclusions: A decrease in lithium prophylactic efficacy in consecutive decades was not observed. Small differences between the bipolar patients entering lithium therapy in the 2 decades were observed in terms of the previous history of illness and during the course of lithium administration. [source] The impact of lithium prophylaxis on the course of bipolar disorder: a review of the research evidenceBIPOLAR DISORDERS, Issue 2 2000Mario Maj A critical review is provided of the available research evidence concerning the efficacy and effectiveness of lithium prophylaxis in bipolar disorder. It is emphasized that, in spite of the limitations of available placebo-controlled trials and naturalistic studies, lithium is the only drug whose prophylactic activity in bipolar disorder is convincingly proved, and remains the first-choice medication in the long-term treatment of bipolar patients. The impact of lithium prophylaxis is likely to be less significant on atypical and comorbid cases of bipolar disorder than in typical manic,depressive illness, but the superiority of other medications over lithium in the long-term treatment of those cases is at present not convincingly proved by research. Currently available research evidence does not seem to support the idea that lithium exerts its prophylactic effect on relapses but not on recurrences of bipolar disorder. Clinicians should be aware of the fact that the drop-out rate in bipolar patients receiving long-term lithium prophylaxis is high even if treatment surveillance is accurate, and that complete suppression of recurrences is a relatively rare outcome of prophylaxis. [source] Randomized study of single early instillation of (2,R)-4,- O -tetrahydropyranyl-doxorubicin for a single superficial bladder carcinomaCANCER, Issue 9 2002Kikuo Okamura M.D., Ph.D. Abstract BACKGROUND Although transurethral resection of a bladder tumor (TUR-Bt) alone has been standard treatment for single superficial bladder carcinoma, some authors reported a certain prophylactic effect of a single immediate intravesical instillation of chemotherapeutic agent after TUR-Bt. A prospective randomized study was conducted to determine whether a single (2,R)-4,- O -tetrahydropyranyl-doxorubicin (THP) instillation immediately after TUR-Bt is beneficial to patients with a single superficial bladder carcinoma. METHODS One hundred seventy patients with a single resectable superficial bladder carcinoma (Ta-1, primary or recurrent with no recurrence during the last 1 year) were enrolled in this study. THP (30 mg/30 mL of normal saline) was administered into the bladder within 6 hours after TUR-Bt in arm A, while TUR-Bt alone was done in arm B. RESULTS Of the 170 patients, 160 (94.1%) were eligible and were followed up for a median time of 40.8 months. There was a significant difference in the recurrence free curve between the 2 arms (log-rank test; P = 0.0026), with 92.4% recurrence free rate at 1 year, 82.7% at 2 years, and 78.8% at 3 years in arm A (84 patients) and 67.0%, 55.7%, and 52.6%, respectively, in arm B. The recurrence rate per year was 0.11 ± 0.22 in arm A and 0.24 ± 0.36 in arm B, with a significant difference (P = 0.007). Toxicity included pain with micturition in 9 patients (10.7%), urinary frequency/urgency in 5 patients (6.0%), and macroscopic hematuria in 7 patients (8.3%). CONCLUSIONS These data indicate that a single THP instillation immediately after TUR reduces the recurrence of superficial bladder carcinoma. Cancer 2002;94:2363,8. © 2002 American Cancer Society. DOI 10.1002/cncr.10496 [source] | |||||||||||||